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Despite new information that the disease
burden of schistosomiasis in Africa may be
equivalent to malaria or HIV/AIDS and a
simple annual anthelminthic treatment for
this disease is available for less than 50
cents per person including delivery costs, we
now know that fewer than 5% of the
infected population is receiving coverage. To
date, this situation represents one of the first
great failures of the ‘‘global health decade’’
that began in 2000.
Although it has not been officially labeled
as such, there are many good reasons to
consider the first years of the 21st century as
the global health decade [1]. Through the
President’s Emergency Program for AIDS
Relief (PEPFAR), the President’s Malaria
Initiative (PMI), the Global Fund to Fight
AIDS, Tuberculosis, and Malaria, and the
sprouting of numerous global health advoca-
cy organizations, tens of billions of dollars
have been committed so far for HIV/AIDS,
tuberculosis, and malaria, i.e., the three
major killer infections of humankind, with
millions of people now placed on treatment
for these conditions. Over the same period,
t h e r eh a v ee v e nb e e ns o m ei m p r e s s i v er e s u l t s
for providing preventive chemotherapy treat-
ments for some of the major neglected
tropical diseases (NTDs). In 2007, an esti-
mated 546 million people received anthel-
minthic treatments for lymphatic filariasis
(LF), or approximately 42% of the population
at risk, while in 2005, 46% of eligible
populations received ivermectin treatments
for onchocerciasis (river blindness) [2]. With
the active involvement of global partnerships
for LF and onchocerciasis, including the
Global Programme to Eliminate LF
(GPELF), the African Programme for On-
chocerciasis Control (APOC), and the Orga-
nization to Eliminate Onchocerciasis in the
Americas (OEPA), together with ongoing
donations from GlaxoSmithKline and Merck
& Co., Inc. to provide albendazole and
ivermectin, respectively, there is great opti-
mism that coverage for these conditions will
continue to increase, and that eventually
these great scourges will some day be
eliminated as public health problems. Two
other NTDs, namely leprosy and human
African trypanosomiasis, are also being
targeted for elimination.
Unfortunately, other NTDs have not fared
so well in terms of coverage. Today it is
believed that fewer than 10% of eligible
populations living in endemic regions of
Africa, Asia, and the Americas are receiving
annual treatments for their schistosomiasis,
intestinal helminth infections, and/or tracho-
ma [2]. The World Health Organization
(WHO) and several leading public private
partnerships and non-governmental develop-
ment organizations are actively working to
correct this situation and to steadily increase
global coverage to the levels of LF and
onchocerciasis. Of these, we believe that the
single largest gap in mass drug administration
for a serious NTD has to be the almost non-
existent global coverage for schistosomiasis.
There are an estimated 207 million people
infected with one of the major schistosomes
[3], with more than 90% of the cases
occurring in sub-Saharan Africa [3,4].
Through a full consideration of the amount
of end-organ pathologies to the liver (in the
case of Schistosoma mansoni and S. japonicum
infections), and to the bladder and kidneys (in
the case of S. haematobium infection) [5],
together with the chronic morbidities associ-
ated with impaired child growth and devel-
opment, chronic inflammation, anemia, and
other nutritional deficiencies, some new
disease burden assessments estimate that
schistosmiasis accounts for up to 70 million
disability-adjusted life years (DALYs) lost
annually [6]. This global burden estimate
exceeds that of malaria or tuberculosis, and is
almost equivalent to the DALYs lost from
HIV/AIDS [6]. Further, almost 300,000
people die annually from schistosomiasis in
Africa [5], and there is evidence that female
genital schistosomiasis caused by S. haemato-
bium may significantly increase the likelihood
of contracting HIV/AIDS [7].
Paired with these devastating health
statistics is the equally alarming finding
that fewer than 5% of the world’s people
with schistosomiasis are today receiving
praziquantel, a specific anthelminthic
treatment that costs as little as 8 cents
per tablet [2]. At the April 2009 NTD
Science and Technical Advisory Group
(STAG) meetings in Geneva, the WHO
reported that compiled statistics given to
them by the member countries confirmed
that fewer than 5% of the estimated
people infected with schistosomiasis actu-
ally received treatment in 2008 (L. Savioli,
personal communication). In Burkina
Faso, annual treatment for a child with
praziquantel (including delivery) has been
shown to cost 32 cents [8]. Annual or
every other year treatment with prazi-
quantel has been shown to improve child
growth and development, and to reverse
the anemia and some of the end-organ
pathologies linked to schistosomiasis
[9,10]. With support from the Bill &
Melinda Gates Foundation, the Schistoso-
miasis Control Initiative (SCI) was created
in 2002 in order to promote increased
access to praziquantel in the at-risk areas
of sub-Saharan Africa [11]. Working in
collaboration with health ministries in six
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million school-aged children received
praziquantel treatments in 2005, 2006,
and 2007, respectively [2,12]. In so doing,
SCI has delivered most of the praziquantel
to national programs providing African
coverage, supplemented by drug dona-
tions from MedPharm, a generic pharma-
ceutical company that utilizes donations
from Canadian citizens. However, an
expansion of these activities in order to
target most of the at-risk populations in
sub-Saharan Africa would require a dra-
matic increase in donations for drugs and
delivery costs if we are to begin approach-
ing the levels of coverage that currently
benefit global populations at risk for LF
and onchocerciasis. A more recent (2009)
grant from the Gates Foundation to the
Global Network for Neglected Tropical
Diseases will mobilize resources for ex-
panding preventive chemotherapy treat-
ments [13], which should help promote
improvements in praziquantel coverage,
but there are still important hurdles that
first must be urgently overcome.
Availability of praziquantel. Throughout
much of sub-Saharan Africa there is
insufficient praziquantel available for
treatment. Praziquantel dosage is one
tablet per 15 kg of body mass, so on
average praziquantel tablet costs are only
20 cents per child and 24–32 cents per
adult dose, depending on weight. Howev-
er, because schistsomaisis is so widespread
and the major control strategy relies on
mass drug administration to either school-
aged children or total populations, even
this modest price exceeds the health
budget of many disease-endemic coun-
tries. In 2008, Merck KgaA (headquar-
tered in Darmstadt, Germany) made an
important first step to ameliorate this
situation by agreeing to donate 200 million
tablets of praziquantel over the next
decade, but this donation still represents
a modest fraction of the drug required
because 20 million tablets per year would
treat just eight million children. According
to a recent WHO stakeholder meeting on
access to essential medicines for NTDs
(Thematic Stakeholder Meeting on Access
to Essential Medicines for Neglected
Tropical Diseases, at International Con-
ference Centre Geneva, Switzerland, 23–
25 March 2009), the United States Agency
for International Development (USAID)
has also donated praziquantel for schisto-
somiasis control in six endemic countries
through their NTD control program, with
additional donations anticipated by the
British Department for International De-
velopment (DFID). Our recommendation
is that approximately US$100 million
annually be made available to purchase
the 1,200 million praziquantel tablets
required each year, for at least 5 years.
With these resources, sufficient praziquan-
tel would be made available to treat
approximately 400 million people annual-
ly (or in some cases every other year) who
are either actively infected with schisto-
somes or who are considered at high risk
for acquiring the infection. In addition to
donations by Merck KgaA, USAID, and
DFID, efforts are being made to reach this
target by the resource mobilization arm of
the Global Network for Neglected Trop-
ical Diseases working together with the
WHO. Other members of the G8 (Group
of Eight countries) may also be mobilized,
with a possible commitment at an annual
G8 summit within the next 2 years. Once
funds are committed, it will be necessary
to ensure adequate manufacturing capac-
ity by coordinating increased production
of the active pharmaceutical ingredient
(API), now mostly done in Asia, and then
formulation into tablets now mostly con-
ducted either in India or South Korea,
or at a Merck KgaA–owned plant in
Mexico.
Praziquantel distribution. Schistosomiasis
exhibits a focal distribution, and the
symptoms are often difficult to recognize
both by the individuals infected and by
health personnel who normally staff the
primary health care facilities in rural
Africa. Additionally, the early stages of
schistosomiasis, when treatment is most
beneficial, often show only mild yet
debilitating symptoms, which lead to
serious consequences later in life. This
means that praziquantel cannot be deliv-
ered in the way that many drugs are
distributed, i.e., by sending them routinely
to the Central Medical Stores and then via
districts to health units. To do so would
result in inefficient and fragmented use of
the drugs because the rural poor infected
with schistosomiasis rarely seek treatment
for their early stage symptoms, and
diagnostic testing is often not performed.
The best way forward for schistosomiasis
control then is for mass drug administra-
tion to be delivered to total at-risk
populations defined where a survey shows
prevalence of over 50% in school-aged
children (although pre-school aged chil-
dren can also be infected), and mass drug
administration to children aged 6–16 years
where survey prevalence is between 10%
and 50% [14]. This regimen would be
repeated until prevalence falls below the
above thresholds. The timeline strategy
recommended by SCI (working with
WHO) is therefore to carry out the
mapping of schistosomiasis distribution
with an assessment of prevalence, conduct
evidence-based advocacy to decision mak-
ers, determine drug needs, order drugs,
and finally train health ministry staff,
teachers, and community drug volunteers
in order to deliver the safe and effective
drugs, receive drugs through the port of
entry, and/or distribute the drugs to rural
centers, followed by mass drug distribu-
tion. Treatments are then repeated annu-
ally in areas of high endemicity and
sometimes every 2 years in areas of lower
endemicity. In terms of costs, we recom-
mend that drug tablet costs should be
accompanied by a budget of approximate-
ly 25 cents for delivery, including advoca-
cy, training, and monitoring and evalua-
tion. Thus, in addition to the $100 million
for praziquantel costs as outlined above,
an additional $100 million is also required
annually to pay for the essential delivery
costs. Used appropriately and when pos-
sible integrated with other NTD control
efforts [2,13], such funds could dramati-
cally reduce schistosome-related morbidity
in Africa.
Operational research. Mass drug adminis-
tration using praziquantel on a large scale
raises many operational research ques-
tions, and all control initiatives should be
accompanied by a budget for operational
research. The range of questions that need
to be addressed include actual costs, drug
efficacy, monitoring for possible develop-
ment of drug resistance, recording com-
pliance, measuring clinical improvement
after treatment through ultrasound and
other technologies, and other clinical
improvements, including growth in chil-
dren and reductions in anemia. Thereaf-
ter, the optimal use of praziquantel will
need to be determined, including frequen-
cy of treatment (annually or every 2 years),
and then an exit strategy once prevalence
and intensity are reduced [15]. Some of
these activities and others are soon to
begin, funded by the Gates Foundation
through the Schistosomiasis Consortium
for Operational Research and Evaluation
(SCORE) (D. G. Colley, personal
communication).
Back-up control tools. There is currently no
strong evidence for the emergence of
praziquantel resistance against schisto-
somes. However, if schistosomiasis control
activities are scaled and over one hundred
millions of at-risk populations receive
praziquantel, it would be wise to consider
this possibility and look into the develop-
ment of a second anthelminthic drug with
an equivalent target product profile [16–
18]. Such upstream activities should be
encouraged under the auspices of the
Special Programme for Research and
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possibly in collaboration with interested
pharmaceutical companies committed to
orphan drug development and major
donors such as the Gates Foundation. First
generation anti-schistosome recombinant
vaccines are under development for S.
mansoni infection (by both the Sabin Vac-
cine Institute and several Brazilian institu-
tions, including the Oswaldo Cruz Foun-
dation, Federal University of Minas Gerais,
and Instituto Butantan) and S. haematobium
infection (by the Institut Pasteur in Lille,
France) [19,20]. Such vaccines could be
used together with praziquantel in a
combined and integrated program of
vaccine-linked chemotherapy [21].
The scaling up of praziquantel manu-
facture and distribution, together with
operational research and new product
research and development, would repre-
sent a global assault on schistosomiasis.
Such activities could reduce one of Africa’s
greatest disease burdens [4], but at a cost
far lower than that associated with better
known conditions such as HIV/AIDS and
malaria [13]. Accordingly, global health
policy makers, major donors (including the
bilaterals and the Gates Foundation), the
WHO, and the major public–private
partnerships devoted to schistosomiasis
control (including SCI and the Global
Network for Neglected Tropical Diseases)
are moving quickly to increase access to
these low-cost, effective treatments in
order to achieve this goal. If successful,
we could avoid a tragic oversight and
grasp an extraordinary opportunity to help
the poorest people in Africa in the context
of an otherwise successful decade of global
health. In 2001, the World Health Assem-
bly adopted a resolution that set as a
global target the regular treatment of at
least 75% of school-aged children at risk
for both soil-transmitted helminth infec-
tions and schistosomiasis by 2010 [22].
Although it is clear that this target will not
be met, it should serve as a wake-up call to
increase our efforts in Africa for schistoso-
miasis control. There is still time to
consign this disease to history [23].
References
1. Hotez PJ (2008) Forgotten people, forgotten
diseases: the neglected tropical diseases and their
impact on global health and development.
Washington (D. C.): American Society of Micro-
biology. 215 p.
2. Hotez P (2009) Mass drug administration and
integrated control for the world’s high-prevalence
neglected tropical diseases. Clin Pharmacol Ther
85: 659–664.
3. Steinmann P, Keiser J, Bos R, Tanner M,
Utzinger J (2006) Schistosomiasis and water
resources development: systematic review, meta-
analysis, and estimates of people at risk. Lancet
Infect Dis 6: 411–425.
4. Hotez PJ, Kamath A (2009) Neglected tropical
diseases in sub-Saharan Africa: review of their
prevalence, distribution, and disease burden.
PLoS Negl Trop Dis 3: e412. doi:10.1371/
journal.pntd.0000412.
5. van der Werf MJ, de Vlas SJ, Brooker S,
Looman CW, Nagelkerke NJ, et al. (2003)
Quantification of clinical morbidity associated
with schistosome infection in sub-Saharan Africa.
Acta Trop 86: 125–139.
6. King CH, Dangerfield-Cha M (2008) The
unacknowledged impact of chronic schistosomia-
sis. Chronic Illn 4: 65–79.
7. Kjetland EF, Ndhlovu PD, Gorno E, Mduluza T,
Midzi N, et al. (2006) Association between genital
schistosomiasis and HIV in rural Zimbabwean
women. AIDS 20: 593–600.
8. Gabrielli AF, Toure S, Sellin B, Sellin E, Ky C,
et al. (2006) A combined school- and community-
based campaign targeting all school-age children
of Burkina Faso against schistosomiasis and soil-
transmitted helminthiasis: performance, financial
costs and implications for sustainability. Acta
Trop 99: 234–242.
9. Koukounari A, Gabrielli AF, Toure S, Bosque-
Oliva E, Zhang Y, et al. (2007) Schistosoma
haematobium infection and morbidity before and
after large-scale administration of praziquantel in
Burkina Faso. J Infect Dis 196: 659–669.
10. Koukounari A, Fenwick A, Whawell S,
Kabatereine NB, Kazibwe F, et al. (2006)
Morbidity indicators of Schistosoma mansoni: rela-
tionship between infection and anemia in Ugan-
dan schoolchildren before and after praziquantel
and albendazole chemotherapy. Am J Trop Med
Hyg 75: 278–286.
11. Fenwick A, Webster JP, Bosque-Oliva E, Blair L,
Fleming F, et al. (2009) The schistosomiasis
control initiative (SCI) rationale, development
and implementation from 2002–2008. Parasitol-
ogy. E-pub ahead of print 27 July 2009.
doi:10.1017/S0031182009990400.
12. Frost LJ, Reich MR (2008) Access: how do good
technologies get to poor people in poor coun-
tries? Cambridge (Massachusetts): Harvard Uni-
versity Press. 249 p. Available: http://www.
accessbook.org/download/AccessBook.pdf. Ac-
cessed 4 September 2009.
13. Hotez PJ, Fenwick A, Savioli L, Molyneux DH
(2009) Rescuing the bottom billion through
control of neglected tropical diseases. Lancet
373: 1570–1575.
14. Fenwick A, Rollinson D, Southgate V (2006)
Implementation of human schistosomiasis con-
trol: challenges and prospects. Adv Parasitol 61:
567–622.
15. Fenwick A, Webster JP (2006) Schistosomiasis:
challenges for control, treatment and drug
resistance. Curr Opin Infect Dis 19: 577–582.
16. Doenhoff MJ, Hagan P, Cioli D, Southgate V,
Pica-Mattoccia L, et al. (2009) Praziquantel: Its
use in control of schistosomiasis in sub-saharan
africa and current research needs. Parasitolo-
gy. E-pub ahead of print 13 March 2009.
doi:10.1017/S0031182009000493.
17. Doenhoff MJ, Cioli D, Utzinger J (2008) Prazi-
quantel: mechanisms of action, resistance and
new derivatives for schistosomiasis. Curr Opin
Infect Dis 21: 659–667.
18. Keiser J, Utzinger J (2007) Artemisinins and
synthetic trioxolanes in the treatment of helminth
infections. Curr Opin Infect Dis 20: 605–612.
19. McManus DP, Loukas A (2008) Current status of
vaccines for schistosomiasis. Clin Microbiol Rev
21: 225–242.
20. Hotez PJ, Bethony JM, Oliveira SC, Brindley PJ,
Loukas A (2008) Multivalent anthelminthic vac-
cine to prevent hookworm and schistosomiasis.
Expert Rev Vaccines 7: 745–752.
21. Bergquist R, Utzinger J, McManus DP (2008)
Trick or treat: The role of vaccines in integrated
schistosomiasis control. PLoS Negl Trop Dis 2:
e244. doi:10.1371/journal.pntd.0000244.
22. Savioli L, Stansfield S, Bundy DA, Mitchell A,
Bhatia R, et al. (2002) Schistosomiasis and soil-
transmitted helminth infections: forging control
efforts. Trans R Soc Trop Med Hyg 96: 577–579.
23. Fenwick A (2006) Waterborne infectious diseases–
could they be consigned to history? Science 313:
1077–1081.
www.plosntds.org 3 September 2009 | Volume 3 | Issue 9 | e485